Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | CLK2 | P49760 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.35 |
| ▸ | CLK1 | P49759 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1302670 | 0.89 | MAP3K5 (0.44) | MAP3K5PIK3CACLK2PIK3CDPIK3CB | |
| SCHEMBL1303590 | 0.87 | MAP3K5 (0.47) | MAP3K5PIK3CACLK2PIK3CDPIK3CB | |
| SCHEMBL1302857 | 0.85 | MAP3K5 (0.44) | MAP3K5PIK3CAMETTL3NPC1RAB9A | |
| SCHEMBL1303814 | 0.82 | MAP3K5 (0.46) | MAP3K5PIK3CACLK2PIK3CDPIK3CB | |
| SCHEMBL1303676 | 0.81 | PIK3CA (0.41) | PIK3CACLK2PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1303780 | 0.81 | PIK3CD (0.42) | MAP3K5PIK3CACLK2PIK3CDPIK3CB | |
| SCHEMBL1302463 | 0.79 | PIK3CD (0.46) | MAP3K5PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1303399 | 0.79 | MAP3K5 (0.46) | MAP3K5PIK3CACLK2PIK3CDPIK3CB | |
| SCHEMBL1303903 | 0.77 | MAP3K5 (0.46) | MAP3K5PIK3CAPIK3CGMETTL3NPC1 | |
| SCHEMBL1304043 | 0.75 | RAB9A (0.47) | PIK3CACLK2PIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | disclosed |
| EP-2178868-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | MAP3K5 192/4885PIK3CA 1/4885CLK2 620/4885 |
| US-20100197682-A1 | Organic Compounds | PIK3CA, PI4KA, PI4KB | MAP3K5 160/4885PIK3CA 1/4885CLK2 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.